Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jan 7, 2025; 31(1): 101463
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101463
Table 1 Demographic and clinical data of all patients, n (%)
Characteristics
First-line treatment, n = 250
Rescue treatment, n = 130
P value
Age in years65.3 ± 4.465.1 ± 3.60.6000
Range60-8260-76
Sex as M/F106/14460/700.5500
Body weight in kg65.5 ± 11.365.8 ± 10.80.8000
BMI in kg/m224.0 ± 3.423.7 ± 2.90.3700
Cigarette smoking31 (12.4)15 (11.5)0.9300
Alcohol drinking35 (14.0)27 (20.8)0.1200
Family history of gastric cancer15 (6.0)15 (11.5)0.0900
Endoscopy diagnosis
        Gastritis193 (77.2)97 (77.2)0.6600
        CSG108 (43.2)32 (24.6)0.0006c
        CAG85 (34.0)65 (50.0)0.0035b
        Peptic ulcer51 (20.4)27 (20.8)1.0000
        Gastric ulcer14 (5.6)11 (4.4)0.4000
        Duodenal ulcer27 (10.8)16 (6.4)0.7900
        Complex (gastric and duodenal) ulcer10 (4.0)0 (0.0)0.0180a
        Gastric cancer1 (0.4)1 (0.8)1.0000
        MALToma3 (1.2)0 (0.0)0.5500
        Gastric hyperplastic polyp2 (0.8)5 (3.8)0.0490a
Combined diseases1.8 ± 1.41.8 ± 1.40.9020
        053 (21.2)26 (20.0)0.8900
        161 (24.4)34 (26.1)0.8000
        264 (25.6)35 (26.9)0.8800
        ≥ 372 (28.8)35 (16.9)0.7900
Combined medicine1.3 ± 1.61.5 ± 1.70.3400
        099 (39.6)45 (34.6)0.4000
        159 (23.6)36 (27.7)0.4500
        240 (16.0)17 (13.1)0.5400
        ≥ 352 (20.8)32 (24.6)0.4700
Comorbidity
        Hypertension89 (35.6)49 (37.7)0.7700
        Diabetes mellitus45 (18.0)20 (15.4)0.6200
        Hyperlipidemia88 (35.2)33 (25.4)0.0700
        Heart disease32 (12.8)15 (11.5)0.8500
        Lung disease10 (4.0)5 (3.8)1.0000
        Liver disease28 (11.2)12 (9.2)0.6800
        Renal disease13 (5.2)7 (5.4)1.0000
        Cerebrovascular disease10 (4.0)7 (5.4)0.6000
        Autoimmune disease24 (9.6)9 (6.9)0.4500
        Hypersensitivity disease4 (1.6)4 (3.1)0.4500
        Other malignant tumor25 (10.0)19 (14.6)0.2400
Adherence247 (98.8)128 (98.5)1.0000
Adverse events23 (9.2); 95%CI: 6.2%-13.4%13 (10.0); 95%CI: 4.8%-15.2%1.0000
Eradication rate95.6% (239/250); 95%CI: 93.0%-98.1%89.2% (116/130); 95%CI: 83.9%-94.6%0.0300a